中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
Chinese Journal of Experimental Surgery
2015年
11期
2863-2865
,共3页
介入治疗%肾细胞癌%生存素%端粒酶
介入治療%腎細胞癌%生存素%耑粒酶
개입치료%신세포암%생존소%단립매
Interventional therapy%Renal carcinoma%Survivin%Telomerase
目的 检测巨型肾细胞癌患者介入治疗前后肾细胞癌组织中生存素(Survivin)、端粒酶(Telomerase)的表达及癌灶体积的变化,观察巨大型肾细胞癌患者介入治疗的临床效果,探讨Survivin、Telomerase的表达及临床意义.方法 对44例巨大型肾细胞癌患者行超选择性肾动脉化疗灌注及栓塞术,比较介入治疗前后癌灶体积的变化;并对介入术前肾肿瘤活检组织和介入术后手术切除的标本,应用免疫组织化学法检测Survivin、Telomerase的表达,同时检测30例癌旁肾脏组织作为对照,探讨介入治疗前后Survivin、Telomerase表达的变化与临床疗效的关系.结果 Survivin、Telomerase在癌旁肾细胞组织中呈低表达(6.67％、3.33％),在肾细胞癌组织中呈高表达(95.45％、97.73％),在介入治疗后Survivin、Telomerase表达呈现明显下降(65.91％、68.18％),差异有统计学意义(P＜0.05),术后行彩超、CT检查发现患者癌灶体积不同程度缩小(t=7.837,P＜0.01)差异有统计学意义(P＜0.05),手术根治机会增加.结论 Survivin、Telomerase与肾细胞癌的发生发展关系密切,Survivin、Telomerase介入治疗后表达明显下降,从而诱导肾细胞癌细胞凋亡,使肿瘤体积缩小,病情好转.
目的 檢測巨型腎細胞癌患者介入治療前後腎細胞癌組織中生存素(Survivin)、耑粒酶(Telomerase)的錶達及癌竈體積的變化,觀察巨大型腎細胞癌患者介入治療的臨床效果,探討Survivin、Telomerase的錶達及臨床意義.方法 對44例巨大型腎細胞癌患者行超選擇性腎動脈化療灌註及栓塞術,比較介入治療前後癌竈體積的變化;併對介入術前腎腫瘤活檢組織和介入術後手術切除的標本,應用免疫組織化學法檢測Survivin、Telomerase的錶達,同時檢測30例癌徬腎髒組織作為對照,探討介入治療前後Survivin、Telomerase錶達的變化與臨床療效的關繫.結果 Survivin、Telomerase在癌徬腎細胞組織中呈低錶達(6.67％、3.33％),在腎細胞癌組織中呈高錶達(95.45％、97.73％),在介入治療後Survivin、Telomerase錶達呈現明顯下降(65.91％、68.18％),差異有統計學意義(P＜0.05),術後行綵超、CT檢查髮現患者癌竈體積不同程度縮小(t=7.837,P＜0.01)差異有統計學意義(P＜0.05),手術根治機會增加.結論 Survivin、Telomerase與腎細胞癌的髮生髮展關繫密切,Survivin、Telomerase介入治療後錶達明顯下降,從而誘導腎細胞癌細胞凋亡,使腫瘤體積縮小,病情好轉.
목적 검측거형신세포암환자개입치료전후신세포암조직중생존소(Survivin)、단립매(Telomerase)적표체급암조체적적변화,관찰거대형신세포암환자개입치료적림상효과,탐토Survivin、Telomerase적표체급림상의의.방법 대44례거대형신세포암환자행초선택성신동맥화료관주급전새술,비교개입치료전후암조체적적변화;병대개입술전신종류활검조직화개입술후수술절제적표본,응용면역조직화학법검측Survivin、Telomerase적표체,동시검측30례암방신장조직작위대조,탐토개입치료전후Survivin、Telomerase표체적변화여림상료효적관계.결과 Survivin、Telomerase재암방신세포조직중정저표체(6.67％、3.33％),재신세포암조직중정고표체(95.45％、97.73％),재개입치료후Survivin、Telomerase표체정현명현하강(65.91％、68.18％),차이유통계학의의(P＜0.05),술후행채초、CT검사발현환자암조체적불동정도축소(t=7.837,P＜0.01)차이유통계학의의(P＜0.05),수술근치궤회증가.결론 Survivin、Telomerase여신세포암적발생발전관계밀절,Survivin、Telomerase개입치료후표체명현하강,종이유도신세포암세포조망,사종류체적축소,병정호전.
Objective To analyze the dynamic expression of Survivin and Telomerase, and the changes in tumor size before and after the interventional therapy in patients with renal cancers.Methods Forty-four patients with renal cancers were given selected renal artery chemotherapy infusion and embolism.The changes in tumor size were observed.Immunohistochemistry was used to detect the expression of Survivin and Telomerase in 30 cases of renal cancer tissues and paired normal renal tissues.Results The expression of Survivin and Telomerase in normal renal tissues (6.67％ and 3.33％) was lower than in the renal cancer tissues (95.45％ and 97.73％).After the interventional chemotherapy infusion and embolism, the expression of Survivin and Telomerase in the renal cancer tissues (65.91％ and 68.18％) was significantly declined (P ＜ 0.05), and the tumor size was significantly lessened (t =7.837, P ＜ 0.01), increasing the opportunity of surgery.Conclusion Survivin and Telomerase are closely related to the occurrence and development of renal cancer.lnterventional chemotherapy is an effective method for the treatment of renal cancer.The expression of Survivin and Telomerase obviously decreased after interventional therapy, thus inducing the apoptosis of renal cancer cells and reducing the tumor size.
